Recombinant Human KDR (N-GST tag)
Catalog No : IGX-RP887
366.40€
0.00€
Shipping cost plus VAT not included , delivery in 7-14 business days
| Product name | Recombinant Human KDR (N-GST tag) | ||
|---|---|---|---|
| Catalog No | IGX-RP887 | ||
| Supplier’s Catalog No | IGX-RP887 | ||
| Supplier | ImuGeX | ||
| Source antigen | Insect cells | ||
| Reactivity | Human | ||
| Cross reactivity | |||
| Applications | |||
| Molecular weight | 110 | ||
| Storage | -70°C | ||
|---|---|---|---|
| Other names | FLK1; VEGFR; VEGFR2 | ||
| Grade | Highly Purified | ||
| Purity | 70% - 90% | ||
| Form | 50mM Tris-HCl, pH 7.5, 150mM NaCl, 0.25mM DTT, 0.1mM EGTA, 0.1mM EDTA, 0.1mM PMSF, 25% glycerol. | ||
| Reactivity life | 6 months | ||
| Note | For reserch purpose only | ||
| Purity | 70% - 90% | ||
| Description | Â KDR (or kinase insert domain receptor) is a growth factor receptor tyrosine kinase that was originally isolated from human endothelial cells where it plays a pivotal role in endothelial cell proliferation and differentiation. KDR and its mouse homolog Flk1 bind VEGF with high affinity and are implicated in the development of new blood vessels (angiogenesis) . The expression levels of VEGF and KDR are highly correlated during the normal development of the ocular vasculature in humans . Induction of angiogenesis is a critical step in tumor progression, and inhibitors of KDR have been demonstrated both to induce tumor regression and reduce metastatic potential in preclinical models . | ||
Product Details
© 2020 Imugex All Rights Reserved